Differential Effect of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Lower-Extremity Amputation Outcomes in Type 2 Diabetes: A Nationwide Retrospective Cohort Study
Diabetes Care · 01.10.2025 · 48 (10) · 1728-1736
DOI: 10.2337/dc25-0292 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Diabetes Care, online erschienen am 25.06.2025. Verfasst von Alexander T Hong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Keck School of Medicine, University of Southern California, Los Angeles, CA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Amputation, Surgical, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Diabetes and Digestive and Kidney Diseases.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE To compare the risk of lower-extremity amputations (LEAs) between new users of glucagon-like peptide 1 receptor agonists (GLP-1RAs) versus sodium–glucose cotransporter 2 inhibitors (SGLT2is). RESEARCH DESIGN AND METHODS This retrospective cohort study used TriNetX, a federated electronic health records network, including adults with type 2 diabetes who initiated GLP-1RAs or SGLT2is between May 2013 and March 2025. Propensity score matching (1:1) was used to balance demographics, comorbidities, medications, and laboratory values. Major (above-ankle) amputation–free survival was evaluated using Kaplan-Meier curves, while risks of major and minor LEAs, diabetic foot ulcers (DFUs), and mortality were estimated using hazard ratios (HRs) with 95% CIs. RESULTS The matched cohorts included 180,740 GLP-1RA and 180,740 SGLT2i recipients. At 3 years, the GLP-1RA cohort was associated with greater major amputation–free survival (99.69% vs. 99.64%, P = 0.001) compared with the SGLT2i cohort. Additionally, GLP-1RA treatment was associated with a lower risk of major LEAs (HR 0.77 [95% CI 0.66, 0.90]), minor LEAs (HR 0.73 [95% CI 0.63, 0.84]), DFUs (HR 0.92 [95% CI 0.87, 0.96]), and mortality (HR 0.66 [95% CI 0.63, 0.69]). Risk reduction for major LEAs remained significant in individuals with peripheral artery disease (HR 0.68 [95% CI 0.56, 0.82]) and DFUs (HR 0.70 [95% CI 0.58, 0.84]). CONCLUSIONS GLP-1RA treatment was associated with greater major amputation–free survival compared with SGLT2i in people with type 2 diabetes, particularly in high-risk subgroups. Prospective studies are needed to confirm findings and inform selection of glucose-lowering therapies for people at risk for diabetes-related amputations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Keck School of Medicine, University of Southern California, Los Angeles, CA.
- Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ.
ORCID-Profile: Tze-Woei Tan
Förderung
- NIDDK NIH HHS
- National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Hong, A. T., Luu, I. Y., Lin, F., Shin, L., Hsu, C. H., Shih, C. D., Armstrong, D. G., & Tan, T. W. (2025). Differential Effect of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Lower-Extremity Amputation Outcomes in Type 2 Diabetes: A Nationwide Retrospective Cohort Study. Diabetes Care, 48(10), 1728-1736. https://doi.org/10.2337/dc25-0292
Vancouver
Hong AT, Luu IY, Lin F, Shin L, Hsu CH, Shih CD, et al. Differential Effect of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Lower-Extremity Amputation Outcomes in Type 2 Diabetes: A Nationwide Retrospective Cohort Study. Diabetes Care. 2025;48(10):1728-1736. doi:10.2337/dc25-0292
BibTeX
@article{Hong2025,
author = {Hong, Alexander T and Luu, Ivan Y and Lin, Forest and Shin, Laura and Hsu, Chiu-Hsieh and Shih, Chia-Ding and Armstrong, David G and Tan, Tze-Woei},
title = {Differential Effect of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Lower-Extremity Amputation Outcomes in Type 2 Diabetes: A Nationwide Retrospective Cohort Study},
journal = {Diabetes Care},
year = {2025},
volume = {48},
number = {10},
pages = {1728--1736},
doi = {10.2337/dc25-0292}
}
EUVIMED